Investor Presentation H1 2023
Therapy
areas
32
Investor presentation
First six months of 2023
Core capabilities and additional technology platforms open up
new opportunities across therapy areas
Diabetes care
Obesity care
CVD
NASH
RBD
RED
Other areas
20
Q0
20
Q0
m
110
Technology platforms
Proteins / Peptides Oligonucleotides / RNAi Stem cells Genome editing / Gene therapy
CO
110
OD
110
O
O
O
O
O
O
1
D
20
O
71
Currently active
Exploratory potential
10
O
Note: Currently active means Novo Nordisk is currently pursuing research projects, while exploratory potential indicates that the platform is potentially applicable for the given disease
RBD: Rare blood disorders; RED: Rare endocrine disorders; CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; RNA: Ribonucleic acid
Injectable administration
B
05
Oral administration
Novo NordiskⓇView entire presentation